3kdd

From Proteopedia
Revision as of 14:22, 29 September 2014 by OCA (talk | contribs)
Jump to navigation Jump to search

Crystal Structure of HIV-1 Protease (Q7K, L33I, L63I) in Complex with KNI-10265Crystal Structure of HIV-1 Protease (Q7K, L33I, L63I) in Complex with KNI-10265

Structural highlights

3kdd is a 2 chain structure with sequence from Human immunodeficiency virus type 1 (bru isolate). Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Ligands:,
Related:3kdb, 3kdc, 2pk5, 2pk6
Gene:gag-pol (Human immunodeficiency virus type 1 (BRU ISOLATE))
Activity:HIV-1 retropepsin, with EC number 3.4.23.16
Resources:FirstGlance, OCA, RCSB, PDBsum

Evolutionary Conservation

Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.

Publication Abstract from PubMed

Binding affinity optimization is critical during drug development. Here, we evaluate the thermodynamic consequences of filling a binding cavity with functionalities of increasing van der Waals radii (-H, -F, -Cl, and CH(3)) that improve the geometric fit without participating in hydrogen bonding or other specific interactions. We observe a binding affinity increase of two orders of magnitude. There appears to be three phases in the process. The first phase is associated with the formation of stable van der Waals interactions. This phase is characterized by a gain in binding enthalpy and a loss in binding entropy, attributed to a loss of conformational degrees of freedom. For the specific case presented in this article, the enthalpy gain amounts to -1.5 kcal/mol while the entropic losses amount to +0.9 kcal/mol resulting in a net 3.5-fold affinity gain. The second phase is characterized by simultaneous enthalpic and entropic gains. This phase improves the binding affinity 25-fold. The third phase represents the collapse of the trend and is triggered by the introduction of chemical functionalities larger than the binding cavity itself [CH(CH(3))(2)]. It is characterized by large enthalpy and affinity losses. The thermodynamic signatures associated with each phase provide guidelines for lead optimization.

How much binding affinity can be gained by filling a cavity?,Kawasaki Y, Chufan EE, Lafont V, Hidaka K, Kiso Y, Mario Amzel L, Freire E Chem Biol Drug Des. 2010 Feb;75(2):143-51. Epub 2009 Dec 17. PMID:20028396[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Kawasaki Y, Chufan EE, Lafont V, Hidaka K, Kiso Y, Mario Amzel L, Freire E. How much binding affinity can be gained by filling a cavity? Chem Biol Drug Des. 2010 Feb;75(2):143-51. Epub 2009 Dec 17. PMID:20028396 doi:10.1111/j.1747-0285.2009.00921.x

3kdd, resolution 1.80Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA